<SEC-DOCUMENT>0001628280-23-036795.txt : 20231103
<SEC-HEADER>0001628280-23-036795.hdr.sgml : 20231103
<ACCEPTANCE-DATETIME>20231103172546
ACCESSION NUMBER:		0001628280-23-036795
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20231103
FILED AS OF DATE:		20231103
DATE AS OF CHANGE:		20231103

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CYBIN INC.
		CENTRAL INDEX KEY:			0001833141
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A6
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40673
		FILM NUMBER:		231377430

	BUSINESS ADDRESS:	
		STREET 1:		100 KING STREET WEST
		STREET 2:		SUITE 5600
		CITY:			TORONTO
		STATE:			A6
		ZIP:			M5X 1C9
		BUSINESS PHONE:		(908) 764-8385

	MAIL ADDRESS:	
		STREET 1:		100 KING STREET WEST
		STREET 2:		SUITE 5600
		CITY:			TORONTO
		STATE:			A6
		ZIP:			M5X 1C9
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>cybininc-form6xk11x03x2023.htm
<DESCRIPTION>6-K
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i9332a41810c2478d8fa63a580d1e6fee_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="-sec-extract:summary;margin-bottom:5pt;margin-top:5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">UNITED STATES<br>SECURITIES AND EXCHANGE COMMISSION</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Washington, D.C. 20549</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><br><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Form 6-K</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><br><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16<br>UNDER THE SECURITIES EXCHANGE ACT OF 1934</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><br></font></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For the month of November, 2023.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Commission File Number&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">001-40673</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Cybin Inc.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(Exact Name of Registrant as Specified in Charter)<br><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(Address of principal executive offices) </font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Form 20-F  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:400;line-height:115%">&#9633;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">  Form 40-F &#8864;</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:10pt"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">SIGNATURE</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.<br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.038%"><tr><td style="width:1.0%"></td><td style="width:5.048%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.398%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.696%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.851%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.507%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">CYBIN INC.</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(Registrant)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">November 3, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">&#47;s&#47; Doug Drysdale&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Name&#58;</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Doug Drysdale</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Chief Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline">EXHIBIT INDEX</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.980%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.820%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">99.1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="cybnmilkenpanelpr11032023f.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">News Release dated November 3, 2023</a></font></div></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>cybnmilkenpanelpr11032023f.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i5ecf68d3da5747e19aef687d8e3029e6_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:133%"> </font><img alt="image_0a.jpg" src="image_0a.jpg" style="height:116px;margin-bottom:5pt;vertical-align:text-bottom;width:200px"></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:133%">Cybin to Participate at the 2023 Milken Institute Future of Health Summit</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:133%">- CEO Doug Drysdale to speak on panel about innovations in mental health care on November 7, 2023 -</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">TORONTO, CANADA </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#8211; November 3, 2023 &#8211; </font><font style="color:#0563c1;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;text-decoration:underline">Cybin</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%"> Inc. (NYSE American&#58;CYBN) (NEO&#58;CYBN) (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">Cybin</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#8221;), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation 2.0 psychedelic treatment options, today announced that Doug Drysdale, Cybin&#8217;s Chief Executive Officer, will be speaking at the 2023 Milken Institute Future of Health Summit on a panel entitled &#8220;Revolutionizing Mental Health Care through Innovation.&#8221; </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#8220;It is an honor to be part of such an important gathering of leading medical experts and scientists.,&#8221; said Doug Drysdale, Chief Executive Officer of Cybin. &#8220;Sadly, there has been little recent progress in addressing the mental health treatment gap and limited effectiveness of current standards of care. This Summit is a welcome opportunity to exchange ideas and foster innovation as we tackle the current mental health crisis.&#8221;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Cybin is focused on developing novel, differentiated therapeutics with the goal of improving clinical outcomes and addressing key unmet needs for people with mental health conditions. Rates of depression have peaked this year, with 17.8 percent of Americans being treated for depression.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:133%;position:relative;top:-3.85pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%"> Current treatments for depression and other mental health conditions have limited effectiveness, creating a mental health treatment gap. Emerging research has demonstrated that psychedelic-based treatment induces a state of plasticity, which may make it easier for people to rewire neuronal circuits. With a rewiring of neuronal circuits, individuals may embrace a new way of thinking, which provides the potential to be effective, during psychedelic-assisted treatment.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:133%;position:relative;top:-3.85pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%"> </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#8220;We are encouraged by our positive interim results showing an unprecedented improvement in depressive symptoms, which could potentially offer therapeutic benefits to help address the current mental health crisis. We look forward to talking about our innovative work at the Milken Summit,&#8221; concluded Drysdale.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">Milken Future of Health Summit&#58; Closing the Gap&#58; Better Health for More People</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%"> </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">Panel title&#58;&#160;&#160;&#160;&#160;</font><font style="color:#0563c1;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%;text-decoration:underline">Revolutionizing Mental Health Care through Innovation</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%"> </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">Date&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Tuesday, November 7, 2023</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">Time&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;9&#58;00am ET</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">Location&#58;&#160;&#160;&#160;&#160;Salamander, Washington DC, 1330 Maryland Avenue, SW</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">Description&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">50% of people will be diagnosed with a mental health condition or disorder at some point in their lifetime. Today, less than 50% of those with mental health conditions seek treatment. This is due to a variety of reasons&#58; stigma, lack of access, lack of resources, lack of education, and lack of confidence in available treatments, among others. This panel will uncover why the treatment gap exists, ideate how this gap could be closed, and explore emerging innovations in the mental health space. To address the growing mental health crisis, there is a need for wide-sweeping intervention to bolster healthy eating, digital technologies, and whole person health, as well as facilitate innovation in burgeoning fields like psychedelics. Only with a truly interdisciplinary approach tackling all components of mental wellbeing can we close the mental health treatment gap, supporting healthier communities, workplaces, and country.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">To access the live panel discussion, please</font><font style="color:#444444;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%"> </font><font style="color:#0563c1;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;text-decoration:underline">click here.</font><font style="color:#444444;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">The archived webcast will also be available on the Company&#8217;s investor relations website on the </font><font style="color:#0563c1;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;text-decoration:underline">Events &#38; Presentations</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%"> page. For more information on the Milken Institute and the upcoming conference visit</font><font style="color:#444444;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%"> </font><font style="color:#499ed6;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">www.milkeninstitute.org</font><font style="color:#444444;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">The Milken Institute is a nonprofit, nonpartisan think tank dedicated to connecting resources and innovation so the best ideas can succeed. This year&#8217;s conference will focus on the most significant issues affecting medical research, preventative care, and public health.</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Witters, Dan. &#8220;U.S. Depression Rates Reach New Highs.&#8221; Gallup, May 17, 2023. https&#58;&#47;&#47;news.gallup.com&#47;poll&#47;505745&#47;depression-rates-reach-new-highs.aspx.&#160;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:133%;position:relative;top:-3.85pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Yasinski, Emma. &#8220;Why Psychedelic Drugs May Become a Key Treatment for PTSD and Depression.&#8221; Smithsonian Magazine, May 3, 2022.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">About Cybin </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Cybin is a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Cybin&#8217;s goal of revolutionizing mental healthcare is supported by a network of world-class partners and internationally recognized scientists aimed at progressing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens. Cybin is currently developing CYB003, a proprietary deuterated psilocybin </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. For company updates and to learn more about Cybin, visit www.cybin.com or follow the team on X, LinkedIn, YouTube and Instagram.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">Cybin Investor &#38; Media Contact&#58;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Gabriel Fahel</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Chief Legal Officer</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Cybin Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1-866-292-4601</font></div><div style="text-align:justify"><font style="color:#0563c1;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;text-decoration:underline">irteam&#64;cybin.com</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%"> &#8211; or &#8211; </font><font style="color:#0563c1;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;text-decoration:underline">media&#64;cybin.com</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%"> </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%"> </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td></tr></table></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_0a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_0a.jpg
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M-5&Q\&5J%C@OP<WXEJV*J4&D"X/4]:LI);]AB^=&N2B/#;6+^Q#1=:84]G#
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MV6H3<5EQ]EX3 ?N4K>8I[MYI1XP.)7=LP"QHF;X_],3561PI.,93K)V:H*/
M5C!E@Q+T!F^W11,3P3,9:/=FREXMP3O_P'AIH-;RSUG0;<8XZ#&J?"."\WP<
M/W94L#\N284>Q$W@)'\+]W1O;-S!GS>#\QV!CPQ\_,0=H5_X8#!_]EZA=C=@
MU]X6K0^\//.H \I#\)7Y)2_QK,]H41Z:=B/  %KYXY=D'KS?@: HEV!^5ZJ>
MO 5=I@VVVD3$#S]T]2A;S1+TH%9AQJ8L"5ZP9S=2E <'T"VD;-<2;J)GS=0$
MD[_@F!YE@Q)\A/YNBR8F*#I'XM)=REXM07<YG!Q6-AET;N 3OEY1\B]4V3P$
M3O2>H"@^8*M\ G"*[P&G>0^TDN.%!Z$G>]!90NOTC2,+SWT!'-=MIB3.BX]1
M20F]LGOB@O7 <3@<6*4.)@_!"Y-+2VFF U_!9%LO3Q*\&.?:XIG!#=O*17$J
MV,H4-XFM+;C'?X$',W$P/CR<]U$MA6K@,$.6&>(L@B[Y_;@HH.R+Y]KJ,S,.
M+R9<G[]1]=32N'(/LB:J$D#K',=[J?*4H/5U+VZH:(LG(BB)$R-<[T_8JR9\
M'HPJR!XBEP,F-H)>;_(% @T(AT:FCI'"WWT:EYT;/1&7"X[R]#A.%XX)GN%"
M!*WN2G'@R/BWVOD^VL'_KPN.$<#7;^/4@\A#1HE-8T.<2;P>H7?."^&&IHJ,
M@-__.8^]@N"A_Q!TJU(%]D\6CIG%:^H]\3IX("O4;W:2EENO\)SGVT.H"SS0
M_X'C6*2M'!7ZXFJSQ'W_RAS3QT70(L))#*J^:L()*UN\*OA>@=W$>0S@_FRZ
M=F7R\RJ5>IZ&$R^4K5J"EMX_ D]\W9IY@E'5^V*<C*/*-$L5N)\X)&$/ 9[U
MPL?0)P6>\UG\,SI1:(W>"RWZ07"@5Y:56#^R>.XKL2<![\1IN(=77+ 6/3V[
M/ F^NC_),G:31'# %]FJF!K@4EOJ^M66\Q-;/#/!TO[]X0%*-80P6= EN^"&
M4NEIUMPN9KCP5NIWE-*L9H$'?#9E(T_!==@ ]:09^TS$"B%VA9=U.55G-1D]
M<$>]K%QEU7N0\>2-5'E*< Q;+K_@GPZE'BM$SQZ1GWYA G:!<669-1,S,7Y;
M6 :.O.5+;(WO/N'0Q[0X+-+.'? 17X)_A@; C[ [OWK8?56X;,'NQG,> ^=Y
M$MZSJ.1ZQG/_&!>L11S [*>?S$@DY6X!)\KKY.N JW?@IOZ>O(95!/?LSHHJ
MO,V:R,3:B_OW-KZ3>1=7H\6OI^;&Q!9U4J<<^LESH$(+9H2RD9N@&S=>*KS6
M5I<[IB2_1M9;1="HV0SO9LV\G.%PX;4XXTZ5IX0.;.U0_]ZV>%W&+H:6KI+I
M\Q1HY^:12;U/'!:!O[]TI]^U2)B^;]WRP3AZ!<>W<1P9AU@PMA2C*: 7'N(,
M/?X[O \KX-TZ.X1G 7ZS$9Z+^DE;QA;+E\8_)BIO5'APJQ:=G<NDQTPF7B<?
MK^^FKR,E^/T8KK2P)E*#@_[0RE!9UX_#%WR<6G6$,[+0!4K4=5WCST_D1/$\
MH86PB;+1J+ 'AA^#+"NHTC Q[Y!\R 2.Z1$<'K'%2<K#_6]&9T"5KR;,&V"+
MUP4<]&<H&_6$O<_M*XEPW!;.90'UNU8)KM'F4,F/Q2<%C/GB%7!NO\%0M,J2
MPILP1G3[Y"&\%_M@LAIPM-<9KW!5H@338.S+5,6-:N+A=,YL: E5%Q#'YY8&
MYN#UHJYC5>F!'FLB$V-*_&?6F?C DP]?#2U.:VH'T(E"]RC1!!!V1VVQFJ"S
MH,KG(3C6VRNV%=)LH)N8>-T_)FH)5.TDTIA &IZ;5 V@-#L@A+Y;HFS4$SBF
M)U+@Q;L;M"CBHY;P0VD/*2:ZJ&\?<*SK</P6CO'*BG*_"ZW.;P:>&#5*;HV4
MN&9TZ/QDK7;X:C1EK3S>7-Q_Q5;#5 '#D]*..^&7%1\":R(U\/"\Q7CI OJ?
MD!*;<+5'M37+&'L7AY!09:<(9]QML9I$I>9\Z.%E>1!:AY^PU30=Z#J^GSH.
M4O B0R/D:[8H2: *Q\$'+56RH*0?C,'!$Y\:>NFC"N":WK\]M"GRQ$>S.E#<
M5!!#VHPOEL+'_G],R3T1KL<9@2\NQ]EUJDQ-P?..$UOQR5E&H1=NM'M6H-TK
MX7I?@PH]=Q7\%Z.)DC?^THRII!%X_EORF#F>Z9BB>PPXM50O0JB<\VWQU 1>
M_[]'7O9Q4'A>>FIE&\),Z]A2)<M.$G[M<8,[6ZPF:5IP2077<#-^#&P5+0$W
M\#->PG A)1X+BOVGVZ(D\#']:MH>3-(UYNALJ?+UA,M6L3RN_H%C2[=\V6IB
MB$G^$#?=FYKM"QL=N($F?*BOH\K6$;GS0W1!W[/7+)V_/TYT6I^5W($FW5H@
MD[0[VU;#U  <3N(XOUCP$IKAN?O9XJG #<W 82<.SIXL?%FAUU(W[ 9:=N^@
MRD\5O&P;;RCU/#&K7PU,% $M!4/9R*K8\6@Y6.JI7W^>Q"%#N'J/.*:IPF,$
M9X(O?=47&JYUZEP7>']L\9J,>BDRYEOA,9>+\XY:A\M?H?M,_::6XF=,RX>2
MY(' CT&:N&04/'/WX@(%:R(?*K[\-%59'H(+\B%;#5.%R!]X6=KN#CQD*U>(
M;!-*&,Y!V4PDZ.I@5]V:J@IVA<CR4P0MLC_;(C7!K7@C/]]L4O!L;HR&^U)E
M2\H#ZT03]?S0H02>,Q\_?+;X3L#O4F>F@NO^/EN\)KB2ARI?2] U_GVPR-D7
MSO$,ZM_K";KK=R0]/AQ.@M:H0]FI)G308;&0+3M3-0S<)*JR1A4H^?#E?D_B
M>+1N!5J%B7-!HN !VXI.*LMD7=D7[TG2S:84:O>!P'??E:3>2"?;T@1>F$0)
M@K%;&6IY*V4CL[3 7E+J:]@HL1/UD^5#C5MUT/*OM2<5=)DOI,K6DO'$1VSQ
MFD"O(U60?=R*5/*",N8,R#)F"0*G^*DTJ]CBF$_"3C7!\6V!=RB_,?";%YRS
M>\5W0ZJR1H6#P;8:I@KQDCTM?T-=OVJ"+^E?(S]]"VHBI"-;:PY>)ES=\2YK
MJB8X5AIYR7:#C+2;*+$#7*.CHWA/<\)&!H%CNL::;CD8JA4H)U&Z/(R<@(]L
M 8I5[\YGF11.D-,W#BE3,B#+5Q%\Z!X/M+@)[FOJN%(,YP)?%"?.3@OTY!+[
M,!R'AQ;V=VS1QL%0AT [J;.SU%/\1=+.YVPU3!4F J73[:B*2Q+3)G+!W\/#
MDVJUS';APPW.]]O65%TPN0-EAU*H!^;88E79%J]R<<[(VK*9*FCI;(:7_ 1K
MON48->\(ZK@HH5/";K$M2@+GDWH!0I+)-'B'#X@\^5NJ?.[2\4>W%_,WV.I3
M@3&=.]FL(OPPP3/MUAHB205N/M:,A X84#R:(A]BMV*\PN=Q72YU#:O)>*YK
MBR<&7HC>S/&@2ER.*>BLJ;H8[29.H (M@B_98B2X+AR>SR7Q.!9\F"D;:86M
MJ_&%M5<!-1-H;9U*'1<E:&4^%OE.S583?E2ILK4$U_*[MGA5L)L<>,W+L+2#
M/#FZHH%%(W$POR\?(FT3@H_3);EM*P[=BD^:A!OQIQ&\2&5,*66K80CB&+P4
M*<Q0& :5-#@=P;UC,&D'='<RK8L'!_J[4)U_@#57%UR3G3C>%1Q$M0F$.%C?
M%Z=F2;]63^"83K;5M!R,1#!%^6?JN"CA_:XW?@D.L>;V&90JOJP9-H7 [SZ<
M1Y;^NE+RS^.7-+:B<87XYJ[P+"5+>H-2(DJT"BD)T#KY,5E) \(6 PY(IQD<
M[D8JF-8M]387<K4MGHA17!>OQ#64K;I2[GI<"F=-):)2=(Z<&+,E[$T1M CO
M'UG4_T9;- 9#3W"%3@6W9B#*-"KXN#^4-"ZU&:09ZD#A$$:]M?SP3*3>1!"<
MXSFV>%7 *9V45^N_FJ!;?5O08.X'!'U-I.5BJ@Y2\&R/^3+QTM>:P$.UD*RD
M 6$7!%JXN6_;.]. A_0TZOK5$G;_;?%$P'VX+,N+  [NP=7#M9<;4D#K,7'@
M-[Q -TS.X'2#?\&S<3(2',TCS7IY1[48L=5-"Z$N)'_107 =-H_4&'K W@R\
M;ZDWE2PGV)8%>DD#5-F\A*WLP'?^.X\EX9@=*O3D'*H>2J%R_H9[*=GBC1%!
MMYNJI!'A>M_<X[!F&!C@#2](NFX8QL\E3) Q,9$DLO<RM!Q</MBSFS67B(DT
M9\EFBM%);A^7PL3#<*RXG"]5T'0FZ8$OV\-M.3@, ^=]/7E<561\YY9:/;I5
M@W/VC'#BCRA;2Z$G%ED358E\^4NJ;!Z*&UJ^N##/G2Z@4?*MI"GVP($_9);,
MKYG8)3$X'D%5THB,AZ$H])8 S 288HNZ=K44.YV$.Z4:73@&\SE2=NI+7)IE
MJQ%<DXP30+3-'84/.[1V3P%GC>OA?PO=J]S'Y:<*MXJHMKE<*P#'<1XZ#^K8
MJJFB9<UU\SA<$^KT$X;@G.ON;0^]BJ9MPX(])-S+RU:5"^ 8/V9\-]'S!^_2
MXV5/O,<6S<ZZTN">:1,7)!%\;2^U53!5@-;#%ZEK5U684487?F"+UP1;)W!?
M4X>F8.L0N]A8WII*19 B$]A$_*-[9Q8'D%6!=BZ#PVQY<#V"P>?4,=42CM_:
MXE4)+Q$'4&7K2UQN39!@ZQ>'=.BRC<DH]ZYZZ?VR@)L"PGN5.)5DQ7<^;8MF
M9ZPT_PV4\48%K9&:7T\F_FH6J&M731B^88;F'F*+5R5.L)RP2SU5T)V^K]IL
M>3WB,:D,ZZ1;)5Q6"TZA[HQT$Y@%]_HM\(%*''Z#PI82E"$394RFC LHB/+U
MA,'IU@0))OV@RC6J^+RT\_T34N[QE 3X4+T3'315+R5HC6<*[-\!\-J?HHPW
M*MPQSU;!$.!0![:*J&M73>!$*_4"D7'O;'""PU3Y)(('?$[6,2J\Y^"DLJ75
M:X' D6T,O<('[>&V#+-T8#^XKM=A*Y\ZKFJ"W_\.%V)8,U7!+9RI\O6$/0XH
M7K55CHL1J'*-RBCQTSSWK9J,62*.@/-*ODFB)^LN]*A)SRZ[/"GTY0\IXXT(
MNV=U]IGN>G";!' XZ9;3363RJ<G$1S'#) -VXXMNV9K)PJQ(RPQ[0[5.T$+Y
MH_%Z<^]"5B-.C.&Y+X36?:;=<[>GDJN'&7(.H<K74U@4M_DUYBW@HY.[;S#:
MO=&:;PI!4;P!WJOD<SQ*_LP6S0:N0,&!;M)X X(OP6T8X&VK80@F)F"<Q+LS
MQM).S66*@>^\"Q[\3*M+ HW[N ^\S)I*#4YN0,LEUS1UN4O+W[1JE1(N)PP\
MY\.5#$'P*(.3'D/B%=9<32I>X4V4C7K"2<=K+JV>YQ=;C%2YK((/]6:X!W77
MZS="94FZ)#5VC#P[&.@=:O$+RG@C@I/XE:V"J<+HXKDOA2]FJ@#XT:(\U!;?
M"7"@GYV(B*#+UI+QQ"9H(1R#8YK67&IP:V'X>*9N 2<5MI0Q;([ZMZ0ROK,<
MU^#;0VX:N/PP+#H%^*#=F[8+OUUP+1,OZTV;P>B?$O?A^+DULQ-Q9G>R7#8%
MNK"L6=WX[>#"$*@K\4:/\*%H+ E-L+CO-6!DC#+>B,"["UL%4P7\@&'+B+I^
MU50FEOZ!XWM*4.S_0-90IHD9<C'/FLL,.&%-V6]8&/;D%2K&D^^ CT[B+8$I
MP7-YKCW<7(F7U2XX9_>@Y.P;^.[7L2=&U9]4T+"YQ>]+'AZ8U8G"?=^(QVS-
M[ 2<1WZY6[6X#QL.UG33J!2= T/M;B"/@1"NK&LHT'_<=P_'I4^4\<94.UD"
ML\LN5US4MT^@G''Z^M$"1^G9XC&1?]X^\!"<"0]HHATU26FYK-$,WYA=/VEL
M:!KA+&Y%B[-P*PV<B"NK!C.-:9DXR!ZSZ(.3.<!HYY!*"9>Q%MXZ,<,^H3$]
M[^T83E/6SN>@(?+C2+LE.-Z&8RK!Q@-@[S_M820B<TM4N?=/WLYX,IB[%)QH
MZJ6DE. #N!4GJ:SIIA(4Y^]O?)%X#-HH]U'<?=463T\PL4-@+A=JNW"=;\5S
M6SX#VFG@+#JTC*ZDKF$UP;W:;'QY=L67'\,)06R9)5V=04J+M?C0V4/*3%@L
MY#ZA!.?Y^T#)]VZ/%$!'#Q^15!^=G:3ET?$!UP"<]3Z1YWP?/W!PO>]!1X..
M#9-13_S7"I.Y*+$))_' Z66_!U,4ZL)@VNB(K&.BV)T?*?;&>[!/)6Y9*Y%+
MVD'X$"W$CY(UW53,\,!^X+!3?6QQKS%;/#W&ZW]?6,QWGWG,N -=A"-M%4QU
M9N'L*W4-6R)HO>*LKCV6S(R4!IX9>OFN>(-6W\JIV_G&2V139KN:JM5+G0.M
M.9(KP('B_N-4V58(';<]E%24O7,S;20'+>H-U;+EHW.%Z]WP(@CX&-Y=\9,E
M\LX#_ BF'?8)BPWL1 Q=L&/AZYYKFBOH OPAT'VOL54P-8#K_S7J&C9;\)!M
M@59(X\O=@$@YGP2'G-^$DI:#U/Y-N'HF;>*.'03'B*U_:XX$[D<?6;85TL[-
M26)"*3#2(_"<U!-8\*[^W)K8"4QAF<=*,J-=MY6; ,9#/VE7ZJ48YMF)BI+'
MY9U'%+Y>&%2<./=D-X,A1=0U;+9"Y9YJ#Z$A-@BQ*SR B^%^-YQM:2)9-":C
MH!.>X*PZU)4X0\]4&<^MN1E>'+>;,6%UHXJ'!O2\#]A#24V\<ZLO4^>*A8_I
M*=;$3HR4&G>BV IM=:ACW(+V9:HME$//_5];/#T5[1X?>&ZNZ^:Q.[1R&G,U
M=AHX641=QV8(!_@#3YZ95YA)Z/6_,6M4P&3%8X]:?'O=\MH9HX)AYPM9DY2
M$ZU8,R2X#)$JUW0I=SV\,W7':NL1I0R7P[%<W(W3%M^)ZS&&'">$R++U!0[Z
MKE$ECK#F6L8-I9YG0MWKJ&.JIB39K*H"7YKCX>'*-W..EE>,#/0\TU;!U %#
M3."FI\X%F47P4IRV8878U5;=,)$2\ZAZTF@B(;7S66NR)JL]YUW0Y;Z;LE-/
MX.R76S,DH9(_H\HU6;\/AMR&DQ$CX(R'"/O5I=TK;5&2%=#+"+U"XD0>DX63
MG?!A[,4=3:VYEH'#/H%*-V$;U$G$4A,XT0^9>(:1-IY%1KL7Y[;Y4W<PJZ('
MSLAC_*F:X@D"+9=4ZRIG86RH9X^@P>XO?#RVPK'-K94K<S+E17$NSFPK@)08
MLF9(REHLH,HU10J<C"?O#;0XS%;?,)$OOY%T6 6?!^,/U VC"HH9T^!AR-VP
MV_*]_+<#QU#:Z9AJR"AW76:'CR$D<5>*,)Q5\,4_WYIG$C+JRY?B?B_4]6Q4
MX*@>C#SA5(L'S JTW%)EH-I)GMA45KA96_*@\GBO=NVN(.W5$3C1GUHS)#A#
M2Y7+6_"^;<3%*+C8PE:="Y@ '3Z4B<(5H?MZ-<;VVJ)5P6XN5;Z6,.X26K U
M-QYL-M!;.9,ZMFH*M;@I\Q 7W,BWY9V0N=*D52$SG=5%YT!,D$%=TZS"@7U<
MY81=,UM-+MB]R+.O'H(6*)3'28W4DPZ!+[] VJPC4V<9Y<3LORA29?,2WE]P
MH">DW2T@"?$]2;IM<C&>C:Y[[8TGWT>6KR&XAK-M\6DC5(6/4<=637#=KL--
M[FSQ=$ 7X% XZ?R6=H&,[_[8FF=2<H5WUO,C[90;#=Z&5N+#T&6[J5P41UG3
MN1(,R^,"G7XV>+N@-;DRZT9Q& 0.K;G487GPHO1;$U7!S&,&KG\\_$'8R"*<
M\<><!L83;I[;8%"$OE.W=P"]S]OMSQ,!U^)VRLY4X5!"X$EU62.K?W(B;58K
MS+!OBZ8'%^O#"Y?OCHK:^;XUSV0 )YJ@6S876ER_Q;$S\AI743R^K=W+0M_]
M2K65*(TR,>$@%B4=?YLJ<&9K1S+&0VX'SC/UOE'@#!+EC<2UUV#_'-P#/8NS
MWB[H4CX$Y_IKM(5+1ELQR8([5^)Q4\<#[_FC>#QEY2;>:AL)E(MQP%67%=M)
MI.OA^LZ=SAU4)S.QNBWY/E;0XOZ$+9J>. -Z,=_$$?#E;3Q3=)>#+1;,0UE9
M(K\$W=[Z,6_:^1.\(&>5U4\/PFX=YK&TIG('Q_*@KDS!]="5_1,&AEM3F8F=
MA7;3+E?^D2U>EWB&%UI4QNM_!S@0!QSA-?"BU8]B\<16;)08Y9RRYF+GE2,+
M"\]*.FF6%^C(C'*'T&E./C9H;9U^S:4+JZ:]JP8F 8_G3O3.S^'$&G7Y#5SI
MU>KSK ?F-IAZO)1P)A]W2[7%TC.",57:[:>,9Q5<<-XF.6>"Q?(U& 9D5.''
MN ($G!C(.0/_[JIB[QMN:&$H":Z#INY[72EG4ZC[/V7-- 2&:8%3FY^JI:[%
MMVWQ3.!*F%$U[XAR41X+S_@7P(%\O>(/?!7NQ^<P#2!F]6]6ZS\M&. ^NE@<
M$0SWGPSG_MD\LB=AFL0Q+5\#YWX<YL: Y^"5/3V[-#VM8%:N73SW&;B3:+7<
M$MB3"I5S?</7!E- X<-%59)5^'!9\XSE5NA>X)I>7!5C_ZHC*7O.JS,'N_MR
M>;UEEVG H2CH]23.&[FZD?713$<2)R/!_!13XK #')[0SF7P(6@X=T1,1><;
MV@$OR[>L:08(/?EIN(GK<8P,5_= ]_RBR/].QVTE'6]"I^1RZI[7$W0O[U^1
M8Y#_=D)__LNI^G:2=FHF'V9F+MA5CX<M??%Y\$VGXP*C\L_$<W/MO>&#F'62
M@))1XF1KNJM9.P0WKLK6*X%R;Q];+)N>H#9/3%$>#%WHU+EGXSC5G)*=4$!K
MXG/QVG.B[NT*M;PBZ5[]#).:>+:U@7"5J:IH>9HUW;54+HTG7WX=JNIY"<#!
M=E0H&+1"_PO76U/G4DT3'V=Q8:-)GVN!0=)03V_5\5'E;H%__R[O^<4TE88"
MIZ<(6@;='&P_"\-9(L^MF[@!KKFT9=J>;3V[/"G3,X(Y2Y?*@ZV9IA+XXJ/0
M&+@3%,=XH@.'#]5C@99+IF,--]-EA+K04++;R>KF99_PPGXFU&ZRX&3?^8HM
MUO: 0_HJ=0[U!-=B@371$B:RFLOO8]!WA E%E/R"_2>&:2[5QNZR"%Z<B[=5
MR98]D\'N.71Y[Z6N"26SM/[:Y79@8G]\-W66J=!S[QJ_Q'V.-=-2<!*K5=M1
M,$P,.("3)\:OZ!<BE;1[Y0K1LX<U/>,)EYVS>Z +/Y@:W%Q+N"V(+=[63,S(
M.S^ASJ&FE+MUK)%LX0S3:81>X8-&.?FDQ//D&MS)TIJ>T>",=:CE):%V_D%>
M"TK:_?WXHK.GI866EGCG1,^YECR/&C*>K&!<K#7#,#,?W"T0G$&BL;QZ"K1S
M\^I%A7^SIF<LZ$ KOKB:N@;5A,X6/E:X++8C9HJ-CE?GI-KY /.BAKY[*L^&
M,UV%63JP7]I]2:H)7KR_CA<+AUO3,PY<USZQ_,U-O7VO46*L79(TU /#DG#W
M2>H\:DJY]U_MN2^T9ABF.\ 0D,@7OR!?BI0R2FXQGOB(-3VC6#:1ANU'QA>W
M4>=>2X'G/ARH0BY;0;0"XSNG4^=13Z'/2;F9+B7RY?>HER*MXOB\&1IP;SSG
MW- 7R<<_)TL7/F/-M#U!L7]_X\F[R/.HHY%B:^)"&:;M*/OB%3BK2KT8J:7=
MDC7;\4S,4(L#XMA#ZESK"%KF6R,M!_/:8;/98.HS.-XYU;+?U)3G7F7-,$SW
M@1,!H9;9-J::(@PXGRF;U8%C^# XPI3;T?Y3T/4?B?SS.F:F&O.%@A/] W4N
MM13BKIT=U-IFF*: &=6I%R2ML$L_XO>]S)KM6 )_(GX619UG/07*N:=36J#;
M@6?@RUG.%S[ UV&R9&N&8;H37.>,*=NHER2M3",I]Z>9.'N[$A?%77'BW)(H
M].6MN .C-=D18#;]P$N^ZFJR*DJ<!R8XK(GI;G 70@P>IUZ2U-(%8\UV#'&2
M:NB^1]K]3=K]C2;+:'&WT85C2B=TSI!&3X.[76*F<VN*8;J;>+N#E"G/2"EW
M"VYK8<VV/9AU'9R($WKI@LNG"L<&QU-N!M8.&.6\'Y,74^=43Z$O9LQ$(L,T
M#';IP)%NH%Z6-(+N\&.A*B3>'&RZ*)5*3X9C/2)0XG+J/-((6O%W&K_SAC$V
M"+&K4=*GSBF)T %;4PS#(-"=_0'ULJ013DX$GAS%O=2MV;8#LTV%RCTUCR6O
M@7(?#K5S?+/W%F\&V'+.NH,GW.??17[?LZTIAF&V RV3U&$N4V6T?#P8EL=9
MDVT#9O,O^^*H0,F_4,>=1O%,MA)_#X<*+[?F.PIT^D8[9>K<Z@D^/H^;DCP-
MQY*M.89AM@,.\"3JQ4DM)=<'\V?O9<U..S@!$GK"@?.[FSS>E )[MXPI\6XP
MW9&.)/"<SU+GE43P ?E;>5B^V9IB&&8RN)%:Y+F_I5Z>M++A+],*!O^#P_MX
MO.Z]@9GW':2=FRL+"R_IU(Q%N)<Z7(N(/+<$@MY*,-+3\Q1KCF&8J8#S^VJC
ML]6H0#F;C2>_-1WCA:L6G?V<L-C_*7CA?YEI*2,EY6X-M'/92''P7VTU'4F@
MQ;=3Y4*=+/P0%>71UA3#,!2XV@:ZX[\D7Z+4$O>!,SW=FFXZZY;W[!9I]P2C
MQ"]#Y3Y,'U,V!=H5G9YT^ ILA?KB#NK\D@BNZ6IKBF&86I1Z>IZ6=17+5&'8
M$[RXO=9TTPATWV'@_*\)M?A'EB6,5:7<+9'G?@7#HFQ5'0LF12'/,:$"56B[
M"4.&:5M"7WX)NF^Y;!^"H32XI')4B2-&%B[,93_R&TH#SX2N^NMP;W3CN\NA
MZ[Z%JKL1@3.^/BJ*+\Z$[7>#Q7VO,5[V:Q1H>?O52P<Z8J,]AFD+PF4+=@\]
ML8AZH;+*:/E7Z!*>W\BNER.+^UX&+<YOX)!#J.6MV/*DZFI$N $=.)SA<@>N
M0J(8&Q)[5)3TL[;0X2/U.'P(W4Z,AV68:66DI^=? BWNI%ZL1@0MR <C+1Q3
M[#WX!FCE83Y+7'..>3Q1VT#8?<:7%N,[X>4_ ,I\O>*[JRA[>0I:M%O18<RD
M&6CX(+RCD<E"N"8/PCW D"Z&8=(2+'+VS;+[8Q*%RMD,SG1MI.42:%4.1-J=
M#7^>'?JR8+2S,/2<5?!W-QLOI\31-624^R@>"\90VE.?$03%V7OA;JS4.2=5
MZ+LA?NRL289ATH+IW<"1_I%ZP6:,E-N+'PPXW1FU$L<H<1YYOBD4E@9>:\TQ
M#).52FG@2.C2W4.]9)TJ:&$]#BW0&RM>X8/V-&<400EZ$<K-M&_2$]+R"FN.
M89A&B7QY*'9YLTY0M)6TN"]4SODXWFI/;T:!W6\XM]ZH@233<8(2S_FP-<DP
M3!ZL*<[?/U3R5]1+US$JN4/81<5]UNUIS3B"DGA#H-T'R/-/*!P+QZ7 UB3#
M,'D"+90YH7+O[9A6J7*W0,OS>K-DYN?!Q%C<R!.-32;%F:KD $9+6+,,P^3)
M"O'-74/M'A]JD<MNH<U4X,LUH2>_,ZKFO=@>_HS&#+LG4]<AC3#EW6I/O,Z:
M9!BF2<S"0&YHY?TD]-W<XTD;E5'R&J/EUX+B_+VZI445[U*@W!NIZY%&E9*\
M",QQSE"&:17@J/;'M=E&.7]L9#*C$4T,+8@[C"^7FV+A6'MH70-^*$+E_+#1
MZP_7\1Z."V68Z6'6J.Y_/3C24P)/YI*7-*F,[UP++_^/P)&_>=7@G#WM\705
M*Q?/?1[T"OY,79\T"K4[VYID&&:ZP&63&!X#+^5*;"%.UM27-HUVL*7E Z#%
MJX?[WFZK[6IP?3QUS=+(:.<.W,3/FF08IAT85;TO#K5X.[1PO@DOZ$\C7UX1
M^@-7!Q,)1.Z!O]MDE+O%>')KG/S#=Q^"+NF#\/_W@OYBE%P?9V/7SF5E)7I#
MW_ET5)2'8LO+5M'U8 9_RBFF%0Z%8$Y9:Y9AF'8#=]L<O\1]3D6=]Q)X:5^%
M>4#'E'Q+H.1[35$>.^K)]P6J\+:@Z!PYIL5AF.[.+)4'1Q?U[1,N.V=W:X:9
M!&[Y 1^:8*I#S*+ <]YES3(,PW0'9MAY/PYM4$XQC3AS/<,P74F<[8IPBJFD
MY5_+0^(5UB3#,$QW4/'DET+M/DXZQA2"ENQ<S.EJS3(,P\Q\<.=1XXM'**>8
M1KCC0-DKO,F:91B&F?E@UG^CQ5FX=0?E&%-)RR6\]0?#,%U%6?4>9'SG%M(I
MIE#@.?]G.%2,89AN(U3B0[@?%.48DPK'4L'.J=8DPS!,US K\F2%<HRII,7:
MT:'^O:U-AF&8[L!H]W.X[)5TC F%*\0"3WS>FF08AND.P@7G[)Y'#M=0RYMF
M<F9_AF$8DD@[)Q@M'Z(<8QI5?'=&;L[', Q3%4P,$JI"0YF:)C)@N?.L289A
MF.ZALM0YT"AY/^4<DPJ[\>%0X>76),,P3/<0*>>3E&-,H\"3)VWCS><8ANDV
M2J43GASY#>[@J>5UUAS#,$QW42D-'$DYQL12[EVK+SSG0&N.81BFNXB\PB#I
M')-*BQ]84PS#,-U%4)R]%W;%2>>81)Z\*ESFOM":8QB&Z2YPJY10B;^1#K*>
MM+@CT'VOL:88AF&Z#^,/?"+PY,.DDZRC4/6_VYIA&(;I2F;A>&;:M?+&$X\9
M+?2ZY3V[63L,PS#=!\9T&BW[*$=92Z%RQRNJ\!)KAF$8ICM!)PHM48=RE-5D
ME+-Y9&'/LZP)AF&8[F4;=.>A*_^CI-UYX\N[X;<\#LHP#+.=<K%P;*B<C933
MW$%:/ )=_Z^M$-_<U19E&(9A;HOZGFZT4R8=YW8IL0E:H9^P11B&89C)K%LJ
M#S88-$]TZXUR_QAJYWC[4X9A&(9BI'3N"XP2)X,SK81%]];0$[^+E..5/>?5
BI5+IR?9G#,/DQBZ[_#__0.%8![*J4     !)14Y$KD)@@@$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
